Loss or decrease in OGG1 levels and increase of 8-oxodG in the genome have been reported in cancer, neurodegenerative diseases, autism, and metabolic diseases [21, 53, 57–62], as well as in brain aging [54, 63, 64]. This evidence concerns the gene OGG1 and metabolic disease.